Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE).

Publication

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE).

Journal Paper/Review - Jul 15, 2022

Sudano Isabella, Mach François, Moccetti Tiziano, Burkard Thilo, Fahe Christian, Delabays Alain, Rickli Hans, Keller Pierre-Fréderic, Dopheide Jörn, Bodenmann Sereina, Fiolka Tom, Ehret Georg, Spirk David

Citation

Sudano I, Mach F, Moccetti T, Burkard T, Fahe C, Delabays A, Rickli H, Keller P, Dopheide J, Bodenmann S, Fiolka T, Ehret G, Spirk D. Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE). Front Cardiovasc Med 2022; 9:953040.

Type

Journal Paper/Review (English)

Journal

Front Cardiovasc Med 2022; 9

Publication Date

Jul 15, 2022

Issn Print

2297-055X

Pages

953040

Brief description/objective

Low-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). In confirmatory trials, proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab substantially lowered LDL-C and reduced cardiovascular morbidity and mortality. However, the routine clinical use of alirocumab in Switzerland has not yet been studied.